Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 19;15(7):e42113.
doi: 10.7759/cureus.42113. eCollection 2023 Jul.

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Heart Failure: An Umbrella Review

Raj Roy  1 , Saketh Vinjamuri  1 , Rishabh Baskara Salian  2 , Nosheen Hafeez  3 , Dakshin Meenashi Sundaram  4 , Tirath Patel  5 , Thulasi Ram Gudi  6 , Advait M Vasavada  7
Affiliations
Review

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Heart Failure: An Umbrella Review

Raj Roy et al. Cureus. .

Abstract

Heart failure remains a leading cause of hospitalization and death, and presents a significant challenge for healthcare providers despite the advancements in its management. This umbrella review aimed to pool the results of meta-analyses on the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in the treatment of heart failure patients. A literature search was done on five databases: PubMed, Cochrane Library, Scopus, Global Index Medicus, and Science Direct for articles with full texts available online. Meta-analyses of five or more randomized controlled trials (RCTs) were included; the assessment of multiple systematic reviews (AMSTAR) was used to assess the quality of included studies. A systematic search identified 10 relevant meta-analyses of RCTs, with primary analyses including outcome data from 171,556 heart failure patients. A pooled review showed that SGLT-2 inhibitors significantly reduced the risk of heart failure hospitalization, cardiovascular death, mortality, serious adverse events, and improved quality of life. SGLT-2 inhibitors are likely safe and effective in managing patients with heart failure especially considering the acute outcomes.

Keywords: cardiology research; heart failure hospitalization; heart failure prognosis; sglt2 inhibitors and heart failure; sodium-glucose cotransporter-2 (sglt-2) inhibitors.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) chart
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Heart disease and stroke statistics—2022 update: a report from the American Heart Association. Tsao CW, Aday AW, Almarzooq ZI, et al. Circulation. 2022;145:0–639. - PubMed
    1. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study. Taylor CJ, Ordóñez-Mena JM, Roalfe AK, Lay-Flurrie S, Jones NR, Marshall T, Hobbs FD. BMJ. 2019;364:0. - PMC - PubMed
    1. Angiotensin-neprilysin inhibition versus enalapril in heart failure. McMurray JJ, Packer M, Desai AS, et al. N Engl J Med. 2014;371:993–1004. - PubMed
    1. Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies. Singh AK, Singh R. Expert Rev Clin Pharmacol. 2019;12:299–308. - PubMed
    1. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs. Kosiborod M, Cavender MA, Fu AZ, et al. Circulation. 2017;136:249–259. - PMC - PubMed

LinkOut - more resources